Cargando…
96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
BACKGROUND: Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings. METHODS: Antiretroviral treatment-experienced patients initia...
Autores principales: | Capetti, Amedeo, Landonio, Simona, Meraviglia, Paola, Di Biagio, Antonio, Lo Caputo, Sergio, Sterrantino, Gaetana, Ammassari, Adriana, Menzaghi, Barbara, Franzetti, Marco, De Socio, Giuseppe Vittorio, Pellicanò, Giovanni, Mazzotta, Elena, Soria, Alessandro, Meschiari, Marianna, Trezzi, Michele, Sasset, Lolita, Celesia, Benedetto Maurizio, Zucchi, Patrizia, Melzi, Sara, Ricci, Elena, Rizzardini, Giuliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394760/ https://www.ncbi.nlm.nih.gov/pubmed/22808029 http://dx.doi.org/10.1371/journal.pone.0039222 |
Ejemplares similares
-
Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010) -
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010) -
Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016) -
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017) -
Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)